Natasha Wauters

Ms. Natasha Wauters

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2023 in Environmental Pollution
Verified
Journal Article
Closed access
ARAndrea Rodriguez-Carrillo
Andrea Rodriguez-Carrillo
SRSylvie Remy
Sylvie Remy
GKGudrun Koppen
Gudrun Koppen
NWNatasha Wauters
Natasha Wauters
Carmen FreireCarmen Freire
Carmen Freire
MFMariana F. Fernández
Mariana F. Fernández

18 August 2023 in Toxics
Verified
Journal Article
Open access
PDF file
BCBianca Cox
Bianca Cox
NWNatasha Wauters
Natasha Wauters
ARAndrea Rodriguez-Carrillo
Andrea Rodriguez-Carrillo
LPLützen Portengen
Lützen Portengen
AGAntje Gerofke
Antje Gerofke
SRSylvie Remy
Sylvie Remy
Early puberty has been found to be associated with adverse health outcomes such as metabolic and cardiovascular diseases and hormone-dependent cancers. The decrease in age at menarche observed during the past decades has been linked to an increased exposure to endocrine-disrupting compounds (EDCs). Evidence for the association between PFAS and phthalate exposure and menarche onset, however, is inconsistent. We studied the association between PFAS and phthalate/DINCH exposure and age at menarche using data of 514 teenagers (12 to 18 years) from four aligned studies of the Human Biomonitoring for Europe initiative (HBM4EU): Riksmaten Adolescents 2016–2017 (Sweden), PCB cohort (follow-up; Slovakia), GerES V-sub (Germany), and FLEHS IV (Belgium). PFAS concentrations were measured in blood, and phthalate/DINCH concentrations in urine. We assessed the role of each individual pollutant within the context of the others, by using different multi-pollutant approaches, adjusting for age, age- and sex-standardized body mass index z-score and household educational level. Exposure to di(2-ethylhexyl) phthalate (DEHP), especially mono(2-ethyl-5-hydroxyhexyl) phthalate (5OH-MEHP), was associated with an earlier age at menarche, with estimates per interquartile fold change in 5OH-MEHP ranging from −0.34 to −0.12 years in the different models. Findings from this study indicated associations between age at menarche and some specific EDCs at concentrations detected in the general European population, but due to the study design (menarche onset preceded the chemical measurements), caution is needed in the interpretation of causality.

7 September 2026 in Biopreservation and Biobanking
Verified
Journal Article
Open access
MHManon Huizing
Manon Huizing
ADAnnelies Debucquoy
Annelies Debucquoy
EBElke Berneel
Elke Berneel
MWMieke De Wilde
Mieke De Wilde
SGStéphanie Gofflot
Stéphanie Gofflot
MFMaartje van Frankenhuijsen
Maartje van Frankenhuijsen
Background: Biobanks are essential infrastructures for biomedical research, yet their long-term sustainability is increasingly challenged by complex and often underestimated costs. While numerous cost-accounting approaches have been proposed over the past decade, comparable empirical data on real-world cost structures and pricing practices remain limited, particularly for academic biobanks operating under nonprofit and regulatory constraints. Objective: To develop and validate a standardized cost visualization and calculation tool (BIOCOST), and to assess its managerial value, in view of sustainability, by applying it across multiple academic biobanks to identify dominant cost drivers, scale effects and discrepancies between calculated costs and real-world pricing. Methods: The BIOCOST tool was developed based on existing frameworks and with input from six BBMRI.be biobanks. Costs are categorized into staffing, Biobank Information Management Systems, and sample storage and processing. The BIOCOST tool provided the basis for estimating total annual costs and cost per sample, corrected for biobank size and activity. Nine biobanks independently populated the tool using a standardized guidance document. Participating biobanks also reported current or intended pricing practices for internal and external users. Results: Total annual biobank costs ranged from €20,270 to €1.5 million, with staffing consistently representing the dominant cost driver. Annual costs per sample varied from €5.86 to €43.81, with higher per-sample costs observed in smaller biobanks, reflecting scale effects. Systematic discrepancies were identified between calculated costs and invoiced prices, particularly for internal biobank users who were frequently charged below costs. Reported pricing strategies revealed undercharging practices associated with hidden costs, institutional policies, and nonprofit constraints. Conclusion: This multi-institutional case study illustrates biobank cost accounting under the Belgian context of strict regulatory and nonprofit constraints. The BIOCOST tool as a managerial instrument highlights substantial cost variability and the persistent gap between costing and pricing, underscoring the need for sustainable funding models.